Access to specialists facilitates appropriate Alzheimer’s disease and related dementia (ADRD) medication use and adherence. However, there is little information on the impact of specialists’ availability on ADRD medication adherence, especially in regions of the United States (US) where specialists are scarce, e.g., the Deep South (DS).
Objective:
To ascertain whether the availability of specialty physicians in the DS and other US regions predicts ADRD medication adherence among community-dwelling older adults
Methods:
We conducted secondary analyses of claims data for 54,194 Medicare beneficiaries with ADRD in 2013–2015. Medication adherence was measured using the proportion of days covered (PDC). Multivariable-adjusted Modified Poisson regression was used to examine associations of adherence with physicians’ availability by region.
Results:
The race/ethnicity distribution was 81.44% white, 9.17% black, 6.24% Hispanic, 2.25% Asian, and 1% other; 71.81% were female, and 42.36% were older than 85 years. Beneficiaries across regions differed in all individual and contextual characteristics except sex and comorbidities. Neurologists and psychiatrists’ availability was not significantly associated with adherence (DS = 1.00, 0.97–1.03 & non-DS = 1.01, 1.00–1.01). Race and having ≥1 specialist visits were associated with a lower risk of adherence in both regions (p < 0.0001). Advanced age, dual Medicare/Medicaid eligibility, and living in non-large metropolitan areas, were associated with adherence in the non-DS region.
Conclusion:
Among older Americans with ADRD, a context defined by specialist availability does not affect adherence, but other context characteristics related to socioeconomic status may. Research should further examine the influence of individual and contextual factors on ADRD treatment among older adults.
Office of the Assistant Secretary for Planning and Evaluation. (2021) What is Alzheimer’s Disease and Related Dementias | ASPE (hhs.gov), Accessed on April 1, 2021.
2.
BorahB, SaccoP, ZarotskyV (2010) Predictors of adherence among Alzheimer’s disease patients receiving oral therapy. Curr Med Res Opin26, 1957–1965.
3.
ArltS LR, RöslerA, von Renteln-KruseW (2008) Adherence to medication in patients with dementia: Predictors and strategies for improvement. Drugs Aging25, 1033–1047.
4.
GeldmacherDS, KirsonNY, BirnbaumHG, EapenS, KantorE, CummingsAK, JoishVN (2014) Implications of early treatment among Medicaid patients with Alzheimer’s disease. Alzheimers Dement10, 214–224.
5.
CampbellNL, DexterP, PerkinsAJ, GaoS, LiL, SkaarTC, FrameA, HendrieHC, CallahanCM, BoustaniMA (2013) Medication adherence and tolerability of Alzheimer’s disease medications: Study protocol for a randomized controlled trial. Trials14, 125.
6.
ParsonsC, LimWY, LoyC, McGuinnessB, PassmoreP, WardSA, HughesC (2021) Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev2, CD009081.
7.
BondM, RogersG, PetersJ, AndersonR, HoyleM, MinersA, MoxhamT, DavisS, ThokalaP, WailooA, JeffreysM, HydeC (2012) The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): A systematic review and economic model. Health Technol Assess16, 1–470.
8.
KnappM, KingD, RomeoR, AdamsJ, BaldwinA, BallardC, BanerjeeS, BarberR, BenthamP, BrownRG, BurnsA, DeningT, FindlayD, HolmesC, JohnsonT, JonesR, KatonaC, LindesayJ, MacharouthuA, McKeithI, McShaneR, O’BrienJT, PhillipsPPJ, SheehanB, HowardR (2017) Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial). Int J Geriatr Psychiatry32, 1205–1216.
9.
OhST, HanKT, ChoiWJ, ParkJ (2019) Effect of drug compliance on health care costs in newly-diagnosed dementia: Analysis of nationwide population-based data. J Psychiatr Res118, 31–37.
10.
MuchaL, ShaohungS, CuffelB, McRaeT, MarkTL, delValle M (2008) Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer’s disease. J Manag Care Pharm14, 451–461.
11.
MaxwellCJ, StockK, SeitzD, HerrmannN (2014) Persistence and adherence with dementia pharmacotherapy: Relevance of patient, provider, and system factors. Can J Psychiatry59, 624–631.
12.
BradyR, WeinmanJ (2013) Adherence to cholinesterase inhibitors in Alzheimer’s disease: A review. Dement Geriatr Cogn Disord35, 351–363.
13.
BartholdD, JoyceG, FeridoP, DraboEF, MarcumZA, GraySL, ZissimopoulosJ (2020) Pharmaceutical treatment for Alzheimer’s disease and related dementias: Utilization and disparities. J Alzheimers Dis76, 579–589.
14.
HernandezS, McClendonMJ, ZhouXH, SachsM, LernerAJ (2010) Pharmacological treatment of Alzheimer’s disease: Effect of race and demographic variables. J Alzheimers Dis19, 665–672.
15.
RaoA, Manteau-RaoM, AggarwalNT (2017) [P1-561]: Dementia neurology deserts: What are they and where are they located in the U.S.?Alzheimers Dement13, P509.
16.
University of Michigan Behavioral Health Workforce Research Center (2018) Estimating the Distribution of the U.S. Psychiatric Subspecialist Workforce. UMSPH, Ann Arbor, MI.
17.
KollerD, HuaT, BynumJPW (2016) Treatment patterns with antidementia drugs in the United States: Medicare Cohort Study. J Am Geriatr Soc64, 1540–1548.
18.
ZuckermanIH, RyderPT, Simoni-WastilaL, ShafferT, SatoM, ZhaoL, StuartB (2008) Racial and ethnic disparities in the treatment of dementia among Medicare beneficiaries. J Gerontol B Psychol Sci Soc Sci63, 328–333.
19.
AmuahJE, HoganDB, EliasziwM, SupinaA, BeckP, DowneyW, MaxwellCJ (2010) Persistence with cholinesterase inhibitor therapy in a populationbased cohort of patients with Alzheimer’s disease. Pharmacoepidemiol Drug Saf19, 670–679.
20.
AndersenRM (1995) Revisiting the behavioral model and access to medical care: Does it matter?J Health Soc Behav36, 1–10.
21.
AmicoKR, MugaveroM, Krousel-WoodMA, BosworthHB, MerlinJS (2018) Advantages to using social-behavioral models of medication adherence in research and practice. J Gen Intern Med33, 207–215.
22.
JaglalSB, GuilcherSJT, BereketT, KwanM, MunceS, ConklinJ, VersnelJ, PackerT, VerrierM, MarrasC, PitzulKB, RiopelleR (2014) Development of a chronic care model for neurological conditions (CCM-NC). BMC Health Serv Res14, 409.
23.
LinCC, CallaghanBC, BurkeJF, SkolarusLE, HillCE, MaglioccoB, EsperGJ, KerberKA (2021) Geographic variation in neurologist density and neurologic care in the United States. Neurology96, e309–e321.
GoodmanRA, LochnerKA, ThambisettyM, WingoTS, PosnerSF LS (2017) Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement13, 28–37.
26.
TaylorDH Jr, FillenbaumGG Ezzel ME (2002) The accuracy of Medicare claims data in identifying Alzheimer’s disease. J Clin Epidemiol55, 929–937.
27.
TaylorDH Jr, OstbyeT, LangaKM, WeirD, PlassmanBL (2009) The accuracy of Medicare claims as an epidemiological tool: The case of dementia revisited. J Alzheimers Dis17, 807–815.
28.
JarrínOF, NyandegeAN, GrafovaIB, DongX, LinH (2020) Validity of race and ethnicity codes in Medicare administrative datacompared with gold-standard self-reported race collected duringroutine home health care visits. Med Care58, E1–E8.
29.
SinghGK (2003) Area deprivation and widening inequalities in US mortality, 1969-1998. Am J Public Health93, 1137–1143.
30.
SharabianiMTAylinP, BottleA (2012) Systematic review of comorbidity indices for administrative data. Med Care50, 1109–1118.
31.
TraversJL, HirschmanKB, NaylorMD (2020) Adapting Andersen’s expanded behavioral model of health services use to include older adults receiving long-term services and supports. BMC Geriatr20, 58.
32.
United States Department of Agriculture, Economic Research Service. Urban Influence Code In.
33.
ThorpeCT, FowlerNR, HarriganK, ZhaoX, KangY, HanlonJT, GelladWF, SchleidenLJ, ThorpeJM (2016) Racial and ethnic differences in initiation and discontinuation of antidementia drugs by Medicare beneficiaries. J Am Geriatr Soc64, 1806–1814.
34.
Van der GoesDN, NeyJP, GarrisonLP (2019) Determinants of specialist physician ambulatory visits: A neurology example. J Med Econ22, 830–839.
35.
SuhDC, ThomasSK, ValiyevaE, ArconaS VL (2005) Drug persistency of two cholinesterase inhibitors: Rivastigmine versus donepezil in elderly patients with Alzheimer’s disease. Drugs Aging22, 695–707.
36.
HoganDB, BaileyP, BlackS, CarswellA, ChertkowH, ClarkeB, CohenC, FiskJD, ForbesD, Man-Son-HingM, LanctôtK, MorganD, ThorpeL (2008) Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ179, 1019–1026.
37.
GilliganAM, MaloneDC, WarholakTL, ArmstrongEP (2012) Racial and ethnic disparities in alzheimer’s disease pharmacotherapy exposure: An analysis across four state medicaid populations. Am J Geriatr Pharmacother10, 303–312.
38.
Gruber-BaldiniAL, StuartB, ZuckermanIH, Simoni-WastilaL, MillerR (2007) Treatment of dementia in community-dwelling and institutionalized Medicare beneficiaries. J Am Geriatr Soc55, 1508–1516.
39.
PisuM, MartinRC, ShanL, PilonietaG, KennedyRE, OatesG, KimYI, GeldmacherDS (2021) Dementia care in diverse older adults in the U.S. Deep South and the rest of the United States. J Alzheimers Dis83, 1753–1765.
40.
PoonI, LalLS, FordME, BraunUK (2009) Racial/ethnic disparities in medication use among veterans with hypertension and dementia: A national cohort study. Ann Pharmacother43, 185–193.
41.
OwnbyRL (2006) Medication adherence and cognition: Medical, personal and economic factors influence level of adherence in older adults. Geriatrics61, 30–35.
42.
DurfeySNM, KindAJH GRet al. (2018) Impact of risk adjustment for socioeconomic status on Medicare advantage plan quality rankings. Health Aff (Millwood)37, 1065–1072.
